Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. It also provides contract manufacturing services. The company was founded in 1967 and is headquartered in Mumbai, India.
Stock data | 2023 | Change |
---|---|---|
Price | $12.53 | N/A |
Market Cap | $1.80B | N/A |
Shares Outstanding | 144.06M | 19.50% |
Employees | 2.74K | N/A |
Shareholder Equity | 36.62B | -12.85% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.32 | N/A |
P/S Ratio | 5.72 | N/A |
P/B Ratio | 0.05 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0020 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $315.48M | N/A |
Earnings | -$74.04M | N/A |
EPS | -38.79 | N/A |
Earnings Yield | -3.10 | N/A |
Gross Margin | 0.5801 | N/A |
Operating Margin | -0.0567 | N/A |
Net income margin | -0.2347 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $916.03M | N/A |
Total Debt | $260.40M | N/A |
Cash on Hand | $17.88M | N/A |
Debt to Equity | 0.0131 | 14.18% |
Cash to Debt | 0.0687 | -60.06% |
Current Ratio | 0.6428 | -20.38% |